Randomized trial of hyperthermia and radiation for superficial tumors
Ellen L Jones1, James R Oleson, Leonard R Prosnitz
1Radiation Oncology, Duke University Medical Center, DUMC Box 3085, Durham, NC 27710, USA. Jones@radonc.duke.edu
Purpose:
Randomized clinical trials have demonstrated hyperthermia (HT) enhances radiation response. These trials, however, generally lacked rigorous thermal dose prescription and administration. We report the final results of a prospective randomized trial of superficial tumors (
Methods:
This trial was designed to test whether a thermal dose of more than 10 CEM 43 degrees C T(90) results in improved complete response and duration of local control compared with a thermal dose of
Results:
One hundred twenty-two patients were enrolled; 109 (89%) were deemed heatable and were randomly assigned. The complete response rate was 66.1% in the HT arm and 42.3% in the no-HT arm. The odds ratio for complete response was 2.7 (95% CI, 1.2 to 5.8; P = .02). Previously irradiated patients had the greatest incremental gain in complete response: 23.5% in the no-HT arm versus 68.2% in the HT arm. No overall survival benefit was seen.
Conclusion:
Adjuvant hyperthermia with a thermal dose more than 10 CEM 43 degrees C T(90) confers a significant local control benefit in patients with superficial tumors receiving radiation therapy.
More Related Videos
09:23Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods
Published on: October 10, 2025
10:23A Computational Modeling Approach to Investigate the Influence of Hyperthermia on the Tumor Microenvironment
Published on: December 1, 2023